

ALLERGAN INC  
Form 8-K/A  
September 29, 2004

Table of Contents

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**September 26, 2004**

Date of Report (Date of earliest event reported)

**ALLERGAN, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**

(State of Incorporation)

---

**1-10269**

(Commission File Number)

---

**95-1622442**

(IRS Employer  
Identification Number)

**2525 Dupont Drive  
Irvine, California 92612**

(Address of principal executive offices) (Zip Code)

**(714) 246-4500**

(Registrant's telephone number, including area code)

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

**ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF  
DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.  
SIGNATURES**

---

**Table of Contents**

This amendment updates the disclosure to Item 5 of the Current Report on Form 8-K filed by Allergan, Inc. ( Allergan or the Company ) on July 28, 2004.

**Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.**

On July 28, 2004, Allergan announced that Trevor M. Jones, Ph.D. was appointed to its Board of Directors as a Class II director. On September 26, 2004, the Allergan Board of Directors voted to modify the class of director and term for Professor Jones. Professor Jones will now serve as a Class I director and his term will expire at Allergan's Annual Meeting of Stockholders in 2005.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALLERGAN, INC.**

Date: September 28, 2004

By: /s/ Douglas S. Ingram

Name: Douglas S. Ingram

Title: Executive Vice President, General  
Counsel and Secretary